Britain, Government, Health, Research, Society

UK health inequality…

LIFE EXPECTANCY & THE GAP BETWEEN RICH AND POOR

Publication of life expectancy figures this week reveals a population living longer, healthier, and according to some analysts, happier lives. The persistent and alarming gap, however, in life expectancy between those at the top and bottom is largely obscured.

Broadly, health has improved, but much at the same rate as it has for over 100 years. Analysis by the Equality Trust, though, has found that in the last 20 years alone, the gap in life expectancy for those in different local authority areas has increased 41 per cent for men, and an astonishing 73 per cent for women.

East Dorset has been declared as the Local Authority with the highest male life expectancy, with men there now expecting to live almost a decade (8.9 years) longer than those in Blackpool, the authority with the lowest life expectancy. The gap is just as striking for women. Those in Purbeck live over 7 years longer than those in Manchester, and there is now a dramatic 18 year difference in ‘healthy life expectancy’ between women living in Richmond (72 years) and Tower Hamlets (54 years).

The reasons for widening health inequalities are complex, but one contributing factor is the huge growth in economic inequality in the UK over the past 30 years.

A well-established social gradient exists for life expectancy and health, with poorer people experiencing worse health than the affluent. A growing body of research suggests that this is because socio-economic inequality is itself a root cause of health inequalities. In short, due to the unequal distribution of income, wealth and power, the wealthy are able to protect and improve their health; the poor are not.

Economic inequality in the UK has grown monumentally since the early 1980s. The richest 10 per cent of households now own 40 per cent of the UK’s wealth. This equates to being 850 times the wealth of the bottom 10 per cent. If income distribution was the same as it was in 1977, the bottom fifth would be £2,000 a year better off and the top fifth £8,000 less. Given this growth in economic inequality, it should not be unsurprising to see a similar growth in inequality in health outcomes. A recent report from Health Scotland argues that the only way to reduce the social gradient in health is to reduce inequality in income and wealth.

Yet, it is not only those at the bottom who should be concerned with widening inequality – it is something that could affect everyone. The socio-economic observations are important to note. Most developed countries enjoy a similar rate of improvement in life expectancy regardless of their rates of economic growth. But, when inequality increases, improvements in health are a little slower (and when it decreases they are a little faster). In the event of a really catastrophic change in inequality occurring this can push health improvements into reverse. This happened in some Eastern European countries following the social and political upheavals of the early 1990s. In these countries life expectancy dropped dramatically, with some still not having made up for the lost ground more than 20 years later.

The complex nature of health inequality poses a number of specific challenges for policy makers. For example, how can government possibly calculate a fair and reasonable retirement age when there are such wide fluctuations in life expectancy in different areas?

There is a real danger that the Coalition Government in the UK will sweep under the carpet the damaging effects of growing disparities in health. A recent Office for National Statistics consultation in response to budget cuts has proposed that statistics on health inequalities no longer be collected. If this proposal is accepted this would create an almost insurmountable barrier to those wishing to identify and address health problems.

Further analysis shows that economic inequality is not only just a health issue. More unequal societies, for instance, are more likely to experience poorer literacy rates, a higher incidence of drug addiction, greater levels of violence and a myriad of other social ills. In the last few days government advisers have called for measures to reduce inequality in order to reduce child poverty and in the removal of barriers to social mobility. Such measures would allow more people to live longer, healthier and more productive lives.

If we want a healthier society the Government must start taking steps now to reduce the UK’s dangerous and corrosively high levels of economic inequality.

Standard

A WORD FROM HIPPOCRATES…

MD Esquire

Dear Mr Browning,

GRONTE: It seems to me you are locating them wrongly: the heart is on the left and the liver is on the right.

SGANARELLE: Yes, in the old days that was so, but we have changed all that, and we now practice medicine by a completely new method.

Arts, Health, Medical
Image
Health, Medical, Research, Science

An alternative to statins for those at risk of heart disease…

ALN-PCS CUTS ‘BAD’ CHOLESTEROL

For those patients unable to take statins, a new type of cholesterol-lowering drug could help those at risk of heart disease, new research has revealed.

The treatment referred to as ‘ALN-PCS’ cuts the levels of ‘bad’ cholesterol by more than half – a reduction similar to statins.

Experimental findings from the first tests in humans do show the potential benefits of an agent that works in a different way to statins. The drug blocks production of a protein that destroys receptors that normally clear harmful LDL cholesterol from the bloodstream.

Related:

The first trial has involved 32 volunteers with high LDL (or ‘bad ‘cholesterol). People from this group were then randomly assigned to receive either an injection of ALN-PCS or a saline placebo.

A single dose of the drug cut LDL levels by as much as 57 per cent. The research findings have been published in the medical journal, The Lancet. The researchers suggest that the bigger the dose, the greater reduction in LDL.

Kevin Fitzgerald, a trial investigator from Alnylam Pharmaceuticals, was integral to developing the new treatment. He says the drug – which would likely be developed in tablet form – could be used for the one in five heart disease patients intolerant or resistant to statins, or even to enhance their effects.

ALN-PCS works by blocking the production of the cholesterol regulator PCSK9 – a protein that destroys low-density lipoprotein (LDL) receptors that normally clear LDL cholesterol from the blood.

Genetic research has shown previously that mutations’ resulting in a rise in PCSK9 activity does lead to a major increase in LDL cholesterol. This contributes to the build-up of plaque inside blood vessels, while genetic variants that cause a reduction in PCSK9 activity are known to lower cholesterol dramatically.

The 32 volunteers selected for the trial, aged between 18 and 65 years old, were deemed to have raised cholesterol levels ranging from between mild to moderate. The volunteers were randomly assigned to receive injections containing one of six doses of ALN-PCS, or saline.

For those given the highest dose of ALN-PCS, LDL cholesterol dropped up to 57 per cent – with an average of 40 per cent overall – compared with the results from those who had taken the saline placebo.

Professor Peter Weissberg is medical director at the British Heart Foundation. He said:

… People with extremely high cholesterol are at increased risk of a heart attack and this approach could offer new hope for those who are resistant to statins.

… These initial results add to growing evidence that blocking the action of a certain protein can dramatically lower ‘bad’ LDL cholesterol.

… More research is now needed to confirm this approach is both safe and effective at preventing heart attacks in the long term before it becomes widely available.

According to further research in the United States, statins may also help keep the mouth as well as the heart healthy. Significantly reduced levels of inflammation associated with gum disease were found in patients taking statin pills for heart conditions.

Dr Ahmed Tawakol, the study leader, and from the Harvard Medical School, said gum and heart disease were often ‘co-existing inflammatory conditions’ and that their chemical biologies ‘may be intertwined’.

Standard